MetaCap

Arvinas (ARVN) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lyell Immunopharma (LYEL) has outperformed Arvinas (ARVN) over the past year, losing 27.9% versus a loss of 43.9%. Over five years, ARVN leads with a -91.8% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $423.0 million), about 1.0 times the size, while Arvinas is growing revenue faster (-0.3% vs -41.0%).

Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -762355.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARVN-43.92%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
ARVN-92.22%LYEL-93.62%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARVN versus LYEL key metrics
MetricARVNLYEL
Share price$6.46$13.80
Market cap$423.03M$441.82M
1-day change-4.15%+1.62%
YTD return-45.53%-55.17%
1-year return-43.92%-27.86%
5-year return-91.75%-92.59%
EPS (TTM)$-0.08$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$262.60M$36.00K
Revenue growth (YoY)-0.30%-40.98%
Net income (latest FY)$-80.80M$-274.45M
Operating margin-45.13%-748344.44%
Net margin-30.77%-762355.56%
52-week high$14.51$45.00
52-week low$6.33$7.20
Distance from 52-week high-55.48%-69.33%
Analyst consensusbuybuy
Avg. price target upside+116.72%+172.68%
Average volume848.52K174.76K
Shares outstanding65.49M32.02M
Employees246161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LYEL has outperformed ARVN by 16.1 percentage points over the past year.
  • Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
  • Arvinas grew revenue faster in its latest fiscal year (-0.30% vs -40.98%).

About Arvinas

ARVN stock →

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

ARVN vs LYEL FAQ

Which is bigger, Arvinas or Lyell Immunopharma?

Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $423.03M for Arvinas (ARVN).

Which stock has performed better over the past year, ARVN or LYEL?

LYEL returned -27.86% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.

Are Arvinas and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons